These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 15961776)

  • 1. Weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients.
    Alliot C
    J Clin Oncol; 2005 Jun; 23(18):4237-8; author reply 4238-9. PubMed ID: 15961776
    [No Abstract]   [Full Text] [Related]  

  • 2. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
    Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
    J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Usefulness of ambulatory adjuvant chemotherapy with low-dose epirubicin in patients with axially-node positive breast cancer: Chiba Epirubicin Cooperative Study Group].
    Miyauchi M; Yamamoto N; Nakajima N; Suzuki M; Takahashi M; Ohno K; Ogawa K; Tsukamoto T; Yamamoto K; Oheda Y;
    Gan To Kagaku Ryoho; 2001 Jan; 28(1):43-8. PubMed ID: 11201379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.
    ; Basser RL; O'Neill A; Martinelli G; Green MD; Peccatori F; Cinieri S; Coates AS; Gelber RD; Aebi S; Castiglione-Gertsch M; Viale G; Price KN; Goldhirsch A
    J Clin Oncol; 2006 Jan; 24(3):370-8. PubMed ID: 16421418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
    Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic (adjuvant) treatment of primary breast cancer.
    Somani N
    J Assoc Physicians India; 2001 Apr; 49():451-3. PubMed ID: 11762618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.
    Mele T; Generali D; Fox S; Brizzi MP; Bersiga A; Milani M; Allevi G; Bonardi S; Aguggini S; Volante M; Dogliotti L; Bottini A; Harris A; Berruti A
    Breast Cancer Res Treat; 2010 Oct; 123(3):795-804. PubMed ID: 20680681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer.
    Benson JR
    J Clin Oncol; 2005 Sep; 23(27):6807-9. PubMed ID: 16170197
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimal chemotherapy for high-risk early-stage breast cancer.
    Atkins CD
    J Clin Oncol; 2010 Jun; 28(16):e263; author reply e264. PubMed ID: 20406917
    [No Abstract]   [Full Text] [Related]  

  • 11. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose chemotherapy and stem cell transplantation does not improve relapse-free or overall survival in women with high-risk breast cancer.
    Carlson RW; Wheatley K
    Cancer Treat Rev; 2004 Feb; 30(1):131-7. PubMed ID: 14766131
    [No Abstract]   [Full Text] [Related]  

  • 13. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
    Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
    J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One more change of paradigm in breast cancer treatment. Postmastectomy radiotherapy for patients with one to three lymph node metastases?
    Sautter-Bihl ML; Sauer R
    Strahlenther Onkol; 2007 Jul; 183(7):357-9. PubMed ID: 17609867
    [No Abstract]   [Full Text] [Related]  

  • 15. Adjuvant chemotherapy for elderly women with hormone receptor-positive breast cancer: an old(er) problem.
    Schott A; Hayes DF
    J Clin Oncol; 2004 Dec; 22(23):4660-2. PubMed ID: 15505274
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial.
    Bottini A; Berruti A; Brizzi MP; Bersiga A; Generali D; Allevi G; Aguggini S; Bolsi G; Bonardi S; Tondelli B; Vana F; Tampellini M; Alquati P; Dogliotti L
    Endocr Relat Cancer; 2005 Jun; 12(2):383-92. PubMed ID: 15947110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
    Battelli N; Massacesi C; Braconi C; Pilone A; Manzione L; Dinota A; Cobelli S; Scanni A; Sturba F; Giacomini G; Morale D; Giorgi F; Tummarello D; Cascinu S
    Am J Clin Oncol; 2006 Aug; 29(4):380-4. PubMed ID: 16891866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
    Cataliotti L; Buzdar AU; Noguchi S; Bines J; Takatsuka Y; Petrakova K; Dube P; de Oliveira CT
    Cancer; 2006 May; 106(10):2095-103. PubMed ID: 16598749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dense treatment prolongs disease-free survival of women with node positive breast cancer.
    Dang C; Seidman AD
    Cancer Treat Rev; 2003 Oct; 29(5):453-6. PubMed ID: 12972365
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.